Yes, it is the diagnostic only, and it is significant: its a $2billion market, and its growing. There are 2 main products at the moment Pylarify (Lantheus) and Illuccix (Telix). Those 2 companies have grown their MCs to around $20billion combined, on one diagnostic product each. So, it's hugely meaningful.
One key is that, even if the 64CU-SAR-BISPSMA product simply proves to have equivalent (non inferior) efficacy to Pylarify and Illuccix (which it wont - its superior), the unmet need, as well as other characteristics of Cu64 are significant differentiators - secondary to the long half-life allowing large scale production capabilities and shipping to any place that is reachable within therange of one flight-time.
One of the key purposes of a PSMA diagnostic is to identify/select patients that are suitable for PSMA targeted therapy - whichever therapy is available. At the moment, its Pluvicto. Thats the space that the Cu6 therapy, 67CU-SAR-BISPSMA, will seek to occupy. Thats some way away: still in P1/P2. Again - a big market.
CU6 Price at posting:
$2.15 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)